paxlovid structure PF-07321332 drug hunter molecules of the year

oral pan-coronavirus antiviral, rev. covalent

Ph. III candidate for COVID-19 (300 mg BID)

from SARS-CoV-1 inhibitor (WO2005113580)

paxlovid (PF-07321332)

Pfizer Worldwide Research

Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which received emergency use authorization from the FDA for Covid treatment at the end of 2021. Clinical…

     this content is exclusive to
    Premium members

    Unlock this content with a Premium membership to read it now.